Cholangiocarcinoma Market Report 2026

The cholangiocarcinoma market size has grown rapidly in recent years. It will grow from $0.62 billion in 2025 to $0.71 billion in 2026 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to increasing incidence of bile duct cancers, limited availability of curative treatments, adoption of chemotherapy as standard care, expansion of oncology treatment centers, growing oncology drug pipelines.

The cholangiocarcinoma market size is expected to see rapid growth in the next few years. It will grow to $1.14 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to increasing development of targeted oncology drugs, rising use of personalized medicine approaches, expansion of clinical trials in rare cancers, growing investment in oncology research, increasing focus on early-stage diagnosis. Major trends in the forecast period include increasing adoption of targeted drug therapies, rising use of combination chemotherapy regimens, growing focus on precision oncology, expansion of immunotherapy research, enhanced emphasis on early diagnosis.

The rising incidence of liver diseases is expected to drive the growth of the cholangiocarcinoma market in the coming years. Liver diseases refer to conditions that impair the normal function or structure of the liver, including hepatitis, cirrhosis, fatty liver disease, and liver cancer. Factors such as obesity, diabetes, alcohol consumption, and viral hepatitis infections are contributing to the increasing prevalence of liver disease. Chronic liver conditions, particularly inflammation and cirrhosis, elevate the risk of cholangiocarcinoma by promoting bile duct damage and malignant cell transformation. For example, in December 2024, the Office for Health Improvement and Disparities, a UK-based government agency, reported that premature deaths from alcoholic liver disease rose 3.6% to 5,984 in 2023, up from 5,776 in 2022. Consequently, the rising incidence of liver disease is driving growth in the cholangiocarcinoma market.

Key companies in the cholangiocarcinoma market are focusing on the development of novel targeted therapies to improve patient outcomes. Targeted therapies are designed to act on specific genes, proteins, or molecules that support cancer cell growth. By blocking the mechanisms that enable tumor progression, these therapies aim to inhibit cancer growth, reduce side effects, and improve treatment efficacy. For instance, in August 2023, Taiho Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, launched LYTGOBI (futibatinib), an FGFR inhibitor for the treatment of unresectable biliary tract cancer with FGFR2 gene fusions. LYTGOBI selectively and irreversibly inhibits FGFR signaling, helping to slow tumor growth and improve outcomes in patients with cholangiocarcinoma (iCCA) that has progressed following chemotherapy.

In July 2023, Lucence, a US-based precision health company, partnered with Innovent Biologics Inc. to advance diagnostics for bile duct cancer. Under this partnership, Innovent will sponsor Lucence’s LiquidMARK Bile Duct test for eligible patients in Hong Kong, enhancing diagnostic accuracy and supporting better treatment decisions. Innovent Biologics Inc. is a China-based biotechnology company focused on developing innovative therapies, including treatments for cholangiocarcinoma.

Major companies operating in the cholangiocarcinoma market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boston Scientific Corporation, Servier Laboratories, Incyte Corporation, Exelixis Inc., Hutchison China MediTech Limited, Zymeworks Inc., Agios Pharmaceuticals Inc., RenovoRx Inc., Specialised Therapeutics Pty Ltd, Ascletis Pharma Inc., Tiziana Life Sciences Ltd., Taiho Pharmaceutical Co. Ltd.

North America was the largest region in the cholangiocarcinoma market in 2025. The regions covered in the cholangiocarcinoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cholangiocarcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the cholangiocarcinoma market by increasing costs of imported oncology drugs, biologics, diagnostic imaging equipment, and clinical research supplies used in cancer treatment and monitoring. Oncology centers in North America and Europe are most affected due to reliance on imported specialty drugs and medical devices, while Asia-Pacific faces cost pressure in pharmaceutical manufacturing and distribution. These tariffs are raising treatment costs and affecting drug availability timelines. However, they are also encouraging domestic drug production, regional clinical research investments, and localized oncology supply chains that support long-term treatment access.

The cholangiocarcinoma market research report is one of a series of new reports that provides cholangiocarcinoma market statistics, including cholangiocarcinoma industry global market size, regional shares, competitors with a cholangiocarcinoma market share, detailed cholangiocarcinoma market segments, market trends and opportunities, and any further data you may need to thrive in the cholangiocarcinoma industry. This cholangiocarcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cholangiocarcinoma is a malignant tumor originating in the bile ducts, which transport bile from the liver to the small intestine. It is characterized by uncontrolled growth of abnormal cells, leading to bile duct obstruction and impaired liver function. Common symptoms include jaundice, abdominal pain, weight loss, and fatigue. Early diagnosis and timely treatment are essential for improving prognosis and disease management.

The main types of cholangiocarcinoma are intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma. ICC is a rare, aggressive form of liver cancer that develops within the bile ducts inside the liver. Treatment options vary depending on the therapy and include drugs such as capecitabine, 5-fluorouracil, oxaliplatin, gemcitabine, and cisplatin. Therapies encompass targeted drug therapy, chemotherapy, and immunotherapy, administered via oral, subcutaneous, or intravenous routes. These treatments are distributed through hospital pharmacies, retail pharmacies, and e-commerce platforms.

The cholangiocarcinoma market consists of revenues earned by entities by providing services such as diagnostic testing and imaging, surgical services, and supportive treatments to manage symptoms and improve patient outcomes. The market value includes the value of related goods sold by the service provider or included within the service offering. The cholangiocarcinoma market also includes sales of advanced imaging systems, molecular diagnostic tests, and drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.